Actelion Pharmaceuticals Ltd.
http://www1.actelion.com/en/index.page
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Actelion Pharmaceuticals Ltd.
Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer
While a combo regimen of Cabometyx and Tecentriq actually showed a lower response rate in lung cancer than a 2020 readout, a doublet of Cabometyx/Keytruda showed promise in head-and-neck cancer.
FDA Plans 2-Day Meeting On Skin Cancer Detection Tools
The advisory panel will discuss ways to ensure the safety of skin lesion analysis systems, and consider the potential down-classification of two computer-aided melanoma detection devices.
EU Accelerated Assessment: Lilly Requests Fast-Track Status, EMA Says No To SIFI And Janssen
Eli Lilly has asked the European Medicines Agency to grant accelerated assessment to its planned EU marketing application for pirtobrutinib. Meanwhile, the agency has rejected requests to fast-track SIFI’s Akantior and Janssen’s Zejula plus Zytiga combination therapy.
Mirati’s Adagrasib Challenger Fails To Differentiate Itself From Amgen’s Lumakras
While adagrasib showed decent efficacy in its pivotal study in NSCLC, some analysts said its inability to outperform Amgen’s Lumakras and its safety profile leave little room for differentiation.
Company Information
- Other Names / Subsidiaries
-
- Ceptaris Therapeutics, Inc. (Yaupon Therapeutics, Inc.)
- CoTherix, Inc